MORSE: Mucin mRNA isoform-based service platform for the monitoring of barrier-related diseases

The mucin research team at the Laboratory of Experimental Medicine and Pediatrics (LEMP) recently developed a novel high throughput sequencing platform encompassing unique mucin mRNA isoform panels that map mucosal barrier dysfunction with the heterogeneity of mucosal diseases, like inflammatory bowel diseases (IBD). Because of the game-changing concept towards a central role for the mucosal barrier function in the therapeutic management of diseases, this biomarker-based platform (MORSE) will reveal response or non-­response to a particular drug on barrier healing in a biological sample, allowing for personalizes therapeutic strategies and better patient stratification and outcome.